Loading organizations...
Based in Lund, Sweden, Cellevate is a biotechnology company that develops proprietary nanofiber technology systems for three-dimensional cell growth in upstream bioprocessing applications. The company provides highly porous nanofiber networks, marketed as Cellevat3d, that enable cells to proliferate and interact in realistic in vitro models, replacing traditional two-dimensional monolayer cultures for life science researchers. Operating with fewer than 25 employees, the enterprise generates under $5 million in annual revenue through the sale of its specialized cell culture products to biomanufacturing clients. In October 2023, the firm secured 39 million SEK, or approximately $3.7 million, in seed financing to accelerate its global commercial launch, backed by lead investor Industrifonden alongside the European Innovation Council Fund and Onsight Ventures. Originating from early academic research conducted at Lund University, Cellevate was founded in 2011 by Maximilian and Lars Montelius.
Cellevate has raised $4.0M across 1 funding round.
Cellevate has raised $4.0M in total across 1 funding round.
Cellevate has raised $4.0M in total across 1 funding round.
Cellevate's investors include Mala Valroy, Amadeus Capital Partners, Balderton Capital, BoxGroup, Craft Ventures, Daffy, FJ Labs, Homebrew, Kurma Partners, Makers Camp, Offline Ventures, #SecretFund.
Cellevate has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in October 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2023 | $4M Seed | Mala Valroy | Amadeus Capital Partners, Balderton Capital, BoxGroup, Craft Ventures, Daffy, FJ Labs, Homebrew, Kurma Partners, Makers Camp, Offline Ventures, #secretfund, Y Combinator, Andreas EHN, Elliot Shmukler, Loic LE Meur, Svetoslava Georgieva, Hermann Hauser | Announced |
Cellevate is a Swedish biotech company founded in 2014 as a spin-out from NanoLund at Lund University, developing the proprietary Cellevat3d™ nanofiber-based platform for advanced cell culture in biopharmaceutical manufacturing.[1][2][3][4] This green deep-tech innovation produces microcarriers that mimic extracellular environments, enabling 3D cell growth with unprecedented surface area, reproducibility, and scalability for therapies like cell/gene treatments and vaccines.[1][4][5] Serving biopharma companies, it solves key upstream bioprocessing challenges—low yields, high costs, and sustainability issues—by boosting productivity (e.g., 13× higher vaccine yields, up to 85% cost reductions) while integrating from lab to commercial scale.[1][5] With $4.35M–$7.2M raised in seed funding (latest ~$3.55M–39M SEK in 2023), Cellevate shows strong growth momentum, planning Cellevat3d™ launches in 2024 and pre-launches like VAX for viral vectors.[2][3][4][5]
The idea for Cellevate emerged in 2011 at Lund University, when four engineering students collaborated with Professor Lars Montelius and Dr. [unspecified] at the world-leading NanoLund nanomaterials center.[3] This academic foundation led to the company's formal founding in 2014 as a spin-out, headquartered in Lund, Sweden's innovation hub.[1][2][3][4] Early focus centered on patenting a nanofiber manufacturing process to create 3D cell culture networks superior to traditional 2D monolayers, addressing limitations in biomanufacturing reproducibility and efficiency.[2][3] Pivotal traction came via seed funding from investors like Industrifonden, European Innovation Council, Onsight Ventures, and others, culminating in a 39M SEK round in October 2023 to fuel global commercialization.[2][3]
Cellevate rides the explosive growth in cell/gene therapies and vaccines, where demand for scalable biomanufacturing surges amid global needs for personalized medicine and pandemic preparedness.[1][5] Timing is ideal: post-COVID highlighted yield/cost bottlenecks in viral production, while nanofiber tech aligns with sustainability mandates and AI-driven biologics design trends.[2][5] Market forces like rising therapy volumes (e.g., Sanofi's AI biologics push) favor its efficiency gains, potentially enabling regional low-cost manufacturing and reshaping the $30B+ vaccines market by 2030.[2][5] As a deep-tech innovator, Cellevate influences the ecosystem by partnering with upstream solutions, accelerating commercialization for biopharma giants and startups alike.[1][3]
Cellevate is poised for breakout with 2024 product launches, leveraging recent funding to scale Cellevat3d™ globally and expand VAX-like variants for high-demand areas like gene therapy vectors.[3][4][5] Trends in sustainable bioprocessing, 3D culture adoption, and cost-pressured pharma will propel growth, potentially capturing share in a market hungry for 10x+ efficiency. Its influence may evolve from niche innovator to ecosystem enabler, powering next-gen therapies—watch for pilot adoptions and Series A as yields validate at scale, transforming biomanufacturing from factory bottleneck to competitive edge.[1][5]